Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors
- 1 January 2018
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 89, 56-63
- https://doi.org/10.1016/j.ejca.2017.11.012
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2016
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trialThe Lancet Oncology, 2016
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 2016
- Management of toxicities of immune checkpoint inhibitorsCancer Treatment Reviews, 2016
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaThe New England Journal of Medicine, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- The neutrophil–lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trialsBritish Journal of Cancer, 2015
- Neutrophil to lymphocyte ratio and cardiovascular diseases: a reviewExpert Review of Cardiovascular Therapy, 2013
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009